Ibogaine for Multiple Sclerosis: What the Evidence Actually Shows
If you're searching for ibogaine and multiple sclerosis, you've probably seen references to a case report describing dramatic brain scan changes in two MS patients. Let's be direct about what that study is and isn't. It is one case report. Two patients. No control group. And it was written by people who own and work at the clinic that treated them. That doesn't mean the findings are wrong, but it means you should read the rest of this page before getting your hopes up.
The Case Report: Who, What, and the Numbers
The only published human data on ibogaine and MS comes from Calvey et al., 2025, published in Frontiers in Immunology. It describes two patients treated at Ambio Life Sciences, a clinic in Tijuana, Mexico, in February 2023.
Patient A was a 41-year-old male veteran with relapsing-remitting MS (RRMS), plus PTSD, major depressive disorder, and a traumatic brain injury from ten years earlier. He received a 1200mg ibogaine hydrochloride flood dose. Three months after treatment, his MRI showed a 71% reduction in lesion volume (from 1,659.8 mm³ to 480.5 mm³) and a 35.6% decrease in the lesion's Apparent Diffusion Coefficient (ADC), a imaging measure that can reflect reduced inflammation or swelling. His fatigue scores dropped 92% on a standard quality of life questionnaire, and he reported later running a 200 mile ultramarathon. His vertigo, notably, did not improve at all, even a year later.
Patient B was a 44-year-old woman with secondary progressive MS (SPMS), plus complex PTSD and severe muscle spasticity that confined her to a wheelchair. She received a lower dose (500mg, and only took half of that due to worsening spasticity during the session). Her brain scans ten months later showed smaller, more mixed changes than Patient A's. Clinically, her HAI mobility score moved from 8 ("restricted to wheelchair") to 7 ("walking limited to several steps with bilateral support"), and she reported continued gradual improvement two years out.
Both patients also received magnesium before dosing (to reduce cardiac risk) and a microdose maintenance regimen (20mg/day) after discharge.
Why This Isn't the Same as Proof It Works
Here's what the study cannot tell you, and what the authors themselves acknowledge: these were not patients who entered a trial designed to test ibogaine for MS. They came to the clinic for other reasons (addiction history, PTSD, TBI) and happened to also have MS. The authors state plainly that "the effects of ibogaine cannot be confirmed to be specific to MS and may have impacted the other neuropsychiatric comorbidities in these patients." In other words, we don't actually know whether the improvements came from an effect on MS itself, or from something else ibogaine did for their PTSD, depression, or overall nervous system that happened to also show up on an MS-relevant brain scan.
The study also has a direct financial conflict of interest, which the authors disclosed themselves: all five authors are affiliated with Ambio Life Sciences, the clinic that treated these patients and sells ibogaine treatment. Two of the authors are shareholders in Ambio. One author is also a shareholder in a company that manufactures ibogaine products. The study was funded by Ambio, and Ambio's funding statement confirms the company was involved in "study design, data collection and analysis, decision to publish, and preparation of the manuscript." None of this makes the data fake. It does mean the people who produced it had a financial stake in a positive result, and no independent researcher has yet replicated these findings.
Beyond the conflict of interest, the basic study design limits what can be concluded: two patients is not a sample size that supports generalization. There was no control group, no placebo arm, and no blinding. Patient A had the more severe-looking before-and-after lesion change, but he also had the less severe form of MS (RRMS, which naturally has periods of improvement, versus Patient B's SPMS, which typically doesn't). Some of what looks like treatment effect in RRMS patients can simply be the disease's normal relapsing-remitting pattern.
How Ibogaine Might Plausibly Affect MS: The Proposed Mechanisms
Separate from this case report, there's a real scientific basis for why someone might hypothesize ibogaine could help MS, even though it hasn't been tested that way. Ibogaine is known to increase glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), both involved in neuronal survival and repair. Animal research has also shown ibogaine upregulates myelination markers (CNP and MBP) in rat brain tissue after chronic morphine exposure, which is relevant to MS since MS is fundamentally a disease of myelin loss (demyelination). You can read more about this specific mechanism on our GDNF and ibogaine neuroplasticity page.
The case report's authors also proposed that ibogaine may reduce neuroinflammation, a central driver of MS progression, based on the decreased ADC values they measured. This is a plausible interpretation of the imaging data, but it remains an interpretation, not a confirmed mechanism in MS patients specifically.
None of these mechanisms have been tested in an actual animal model of MS (such as the standard EAE mouse model researchers use to study MS treatments). The GDNF and myelination research cited above comes from studies of opioid exposure and alcohol consumption, not demyelinating disease.
What Ibogaine Treatment Would Involve for an MS Patient
Ibogaine carries serious, well-documented cardiac risks, covered in detail on our ibogaine and QT prolongation page. For an MS patient specifically, there are additional open questions no published research has addressed:
- Interactions between ibogaine and common MS medications (disease-modifying therapies like dimethyl fumarate, glatiramer, interferons, or newer options) have not been studied
- Autonomic dysfunction, which some MS patients experience, could complicate the cardiac monitoring that ibogaine treatment requires
- Mobility limitations and spasticity, as seen in Patient B, may affect how safely a patient can be monitored and supported during the acute dosing phase
- Whether the specific MS subtype (relapsing-remitting versus progressive) affects outcomes is unknown beyond this one case comparison
Both patients in the case report underwent extensive pre-treatment cardiac screening, continuous monitoring for 12 hours post-dose, and magnesium pre-treatment specifically to reduce arrhythmia risk. Any clinic considering treating an MS patient should be doing at minimum this level of precaution, and should be asked directly how many MS patients they've treated and what happened to them.
The Honest Bottom Line
One industry-funded case report describing two patients is a reason for cautious scientific interest, not a reason to book a flight. If you have MS and are considering ibogaine, know that you would be doing something no controlled study has evaluated, guided by a single published example with a significant financial conflict of interest built into how it was produced and reported. That doesn't make it wrong. It means you're in genuinely uncharted territory, and any provider should be transparent with you about exactly that.
If more case reports, or ideally an actual trial with a control group, are published on ibogaine and MS, we will update this page.
